Surf Air Mobility

AEGLEA BIOTHERAPEUTICS (NASDAQ: AGLE) STOCK QUOTE

Last Trade: US$12.01
Volume: 0
5-Day Change: 17.17%
YTD Change: 6.76%
Market Cap: US$48.640M

LATEST NEWS FROM AEGLEA BIOTHERAPEUTICS

Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023 Biotechnology leader Cameron Turtle , DPhil, appointed as Chief Executive Officer and Member of the Board of Directors alongside industry veterans Jeffrey Albers and Laurie Stelzer Management team with deep IBD experience expanded to advance pipeline of product candidates designed to improve both efficacy and convenience of therapies... Read More
WALTHAM, Mass. , Nov. 22, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 351,750 shares... Read More
Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a half-life extended anti-α4β7 antibody, is on track for an expected IND filing in the first half of 2024, with interim healthy volunteer, proof of concept pharmacokinetic data expected year-end 2024 SPY002, a half-life extended anti-TL1A antibody with potential best-in-class picomolar binding affinity for... Read More
WALTHAM, Mass. , Nov. 3, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 729,600 shares... Read More
WALTHAM, Mass. , Oct. 30, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the following investor conferences: Guggenheim 5 th Annual Inflammation & Immunology Conference, New York, New York –... Read More
WALTHAM, Mass. , Oct. 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that, Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 2,900,000... Read More
WALTHAM, Mass. , Sept. 14, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the Stifel 2023 Immunology & Inflammation Virtual Summit. Chief Operating Officer Cameron Turtle , DPhil, will be... Read More
WALTHAM, Mass. , Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced it will effect a reverse stock split of all outstanding shares of Aeglea's common stock at a ratio of 1-for-25. Aeglea expects its common stock to begin... Read More
Scott Burrows , former Arcutis Biotherapeutics CFO, assumes role as Chief Financial Officer Heidy Abreu King-Jones , former Provention Bio CLO & Corporate Secretary, assumes role as Chief Legal Officer & Corporate Secretary Appointments strengthen Aeglea's leadership team and provides robust financial and corporate stewardship as the company advances a potentially best-in-class inflammatory bowel disease (IBD) portfolio,... Read More
Acquisition of Spyre's assets and concurrent oversubscribed $210.0 million private investment positions the company to advance a potentially best-in-class inflammatory bowel disease (IBD) portfolio, including α4b7 and TL1A programs Sale of legacy pipeline candidate, pegzilarginase, further streamlines operations and increases focus on IBD strategy $236.7 million of cash and cash equivalents and restricted cash as of June 30,... Read More
Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone payments Marketing Authorisation Application for pegzilarginase is under review by the European Medicines Agency WALTHAM, Mass. , July 27, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company... Read More
AUSTIN, Texas and WALTHAM, Mass. , June 23, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc. ("Spyre"), a majority of the independent members of Aeglea's Board of Directors approved the grant of stock options to new employees (including the new members of management) as equity inducement awards under the Aeglea... Read More
Acquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory bowel disease (IBD) portfolio Spyre, the second spinout from Paragon Therapeutics, is advancing a pipeline of product candidates, led by SPY001 and SPY002, that are potentially best-in-class antibodies targeting a4b7 and TL1A, respectively, and which are expected to enter the clinic in... Read More
$39.8 million of cash and cash equivalents, marketable securities, and restricted cash as of March 31, 2023 AUSTIN, Texas , May 11, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) today announced financial results for the first quarter 2023. First Quarter 2023 Financial Results As of March 31, 2023 , Aeglea had available cash and cash equivalents, marketable securities and restricted cash of $39.8 million.... Read More
Results from Cohorts 1 and 2 Showed a Dose-Dependent Reduction in Total Homocysteine Levels Results from Cohort 3 Indicated Additional Dose Exploration and Data from Longer Treatment Duration May be Needed AUSTIN, Texas , April 12, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing human enzyme therapeutics to benefit people with rare metabolic diseases, today... Read More
AUSTIN, Texas , March 17, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the company granted non-qualified equity awards to four new employees with a grant date of March 17, 2023 , as equity inducement awards outside of the company's 2016 Equity... Read More
Jeffrey Goldberg , experienced biotech executive, appointed president and CEO; further strengthened senior management team with appointments of chief medical officer and chief product officer $57.3 million of cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2022 , which is expected to fund operations into the fourth quarter of 2023 AUSTIN, Texas , March 2, 2023 /PRNewswire/ -- Aeglea... Read More
Streamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creation Cortney Caudill , M.B.A., has been promoted to the newly created role of chief product officer to increase focus and efficiency in the advancement of clinical programs AUSTIN, Texas , Jan. 6, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company... Read More
AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the compensation committee of its board of directors has granted non-qualified stock options to purchase an aggregate of 1,884,838 shares of Aeglea's common stock to... Read More
AUSTIN, Texas , Nov. 15, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that Linda Neuman , M.D., M.B.A. has been appointed chief medical officer. Dr. Neuman's appointment is an internal promotion from her previous role as Aeglea's senior vice... Read More
GreenStockNews
Interim Clinical Data from Phase 1/2 Trial of Pegtarviliase Expected in Fourth Quarter of 2022; Currently Dosing Cohort 3 at 1.35 mg/kg MAA for Pegzilarginase for the Treatment of Arginase 1 Deficiency Accepted for Review by the EMA $75.2 Million of Cash as of September 30, 2022 ; Runway into Fourth Quarter of 2023 Aeglea... Read More
GreenStockNews
Event to be Held Thursday, October 27 th at 10 AM ET Aeglea BioTherapeutics, Inc . (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that it will host a key opinion leader (KOL) webinar on Classical... Read More
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that dosing in the third cohort of the Phase 1/2 clinical trial of pegtarviliase for the treatment of Classical Homocystinuria is underway. Patients in this cohort are receiving 1.35 mg/kg of pegtarviliase once weekly... Read More
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced oral and poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 being held in Freiburg, Germany August 30 – September 2 . The presentations include perspectives on... Read More
Prioritizing Resources and Focus on AGLE-177 and the Completion of the Ongoing Phase 1/2 Trial in Homocystinuria with Interim Clinical Data Expected in Q4 of 2022 Dr. Anthony Quinn , President, CEO and Board Member, has Stepped Down from His Current Positions and Transitioned to an Advisory Role Corporate Restructuring to Extend Runway into Q4 2023 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology... Read More
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that a Marketing Authorization Application (MAA) for pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D) has been submitted to and successfully validated by the European Medicines Agency (EMA). The MAA was... Read More
Cohort 2 Completed in Phase 1/2 Trial of AGLE-177; Data Expected in Fourth Quarter of 2022 Actively Engaged with FDA to Identify Potential Paths Forward for Pegzilarginase Gross Proceeds of $45 Million from May 2022 Registered Direct Offering Extends Cash Runway Through the Second Quarter of 2023 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme... Read More
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding the company's Biologics License Application (BLA) for pegzilarginase for the treatment of Arginase 1 Deficiency... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the... Read More
GreenStockNews
Pegzilarginase BLA submitted to the FDA; if approved, pegzilarginase would be the first FDA-approved treatment for Arginase 1 Deficiency Additional PEACE data supporting potential efficacy of pegzilarginase presented at SIMD Enrollment continues in Phase 1/2 trial of AGLE-177; IND now open for U.S. site initiation Aeglea... Read More
GreenStockNews
BLA submission provides FDA with all pegzilarginase program data to review in detail; Aeglea looks forward to working collaboratively with the FDA on next steps in the review process If approved, pegzilarginase would be the first FDA-approved treatment for this devastating rare disease European marketing application on track... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today shared additional data from the PEACE Phase 3 study during a poster presentation at the Society for Inherited Metabolic Disorders... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in two investor conferences as follows: Conference: 21 st Annual Needham Virtual Healthcare Conference,... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced poster presentations at two upcoming medical meetings. The Company will present additional data from the PEACE Phase 3 study... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, announced today the withdrawal of the previously announced, proposed public offering. We are well capitalized, with cash and cash... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock and, in lieu... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that it will host a Key Opinion Leader (KOL) and Patient Caregiver Webinar on Arginase 1 Deficiency on Thursday, February 3,... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in two investor conferences as follows: Conference: 40th Annual J.P. Morgan Health Care Conference,... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the pivotal Phase 3 study, PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints), met the... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it will host an investor conference call and webcast tomorrow morning to discuss the topline results from the... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Hunter C. Smith to its board of directors. Mr. Smith currently serves as the chief financial... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2021 , and reviewed recent corporate updates and program... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that seven abstracts will be presented at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) 2021 being... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in the following medical and investor conferences: Investor Meetings 2021 Wells Fargo Virtual Healthcare... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2021 , and reviewed recent corporate updates and program... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Jim Kastenmayer , Ph.D., J.D., as general counsel. "With his broad experience at both big pharma and... Read More
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the publication of 20 week data from the Phase 1/2 clinical trial of pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D), a rare, progressive and devastating disease characterized by high levels of the... Read More
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Jonathan D. Alspaugh as Chief Financial Officer. "Jonathan brings a wealth of experience and insights to Aeglea from his previous roles advising healthcare companies on strategic, financial and... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the dosing of the first patient in the Company's first-in-human Phase 1/2 clinical trial investigating AGLE-177 for... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Marcio Souza to its board of directors. Mr. Souza serves as the president & chief executive officer... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today reported its first quarter 2021 financial results, and provided recent corporate and program highlights. "We've had a strong... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced the launch of THINK ARGININE, a disease education initiative focused on improving the awareness and diagnosis of Arginase 1... Read More
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it has completed patient randomization for PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints), the pivotal Phase 3 clinical trial investigating pegzilarginase for the treatment of Arginase 1... Read More
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will participate in two virtual investor conferences in April 2021 . Conference Details Conference Name: 2021 Virtual Wells Fargo Biotech Corporate Access Day Conference Date: Tuesday, April 6 and Thursday, April 8... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, and Immedica Pharma AB (Immedica) today announced the license and supply agreement for pegzilarginase, a novel, recombinant human... Read More
GreenStockNews
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today reported its fourth quarter and full year 2020 financial results, and provided recent corporate and program highlights. "2020 was... Read More
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Sara Brownstein to its board of directors. Ms. Brownstein serves as a principal at Baker Bros. Advisors LP. "I am very pleased to welcome Sara to our board of directors at this important stage in... Read More
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the company's chief financial officer, Charles N. York II , will be leaving the company effective February 12, 2021 to serve in an expanded chief operating officer and chief financial officer role at an emerging... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS